This inventor holds 1 USPTO granted patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Hidenobu Kamohara: Innovator in DDR1 Research
Introduction
Hidenobu Kamohara is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of biomedical research, particularly in the modulation of the discoidin domain receptor 1 (DDR1). His work has implications for understanding various cellular processes and potential therapeutic applications.
Latest Patents
Hidenobu Kamohara holds a patent titled "Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway." This patent discloses methods for modulating the activity of DDR1. It includes methods for screening agents that activate DDR1, inducing the maturation of immature macrophages and dendritic cells, increasing neutrophil activation, and enhancing leukocyte migration using DDR1 activating agents. This patent represents a significant advancement in the understanding of DDR1's role in immune response and tissue remodeling.
Career Highlights
Kamohara's career is marked by his dedication to research and innovation in the biomedical field. He is currently associated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has contributed to the advancement of knowledge in receptor biology and its applications in health and disease.
Collaborations
Hidenobu Kamohara has collaborated with Teizo Yoshimura, further enhancing the impact of his research. Their combined expertise has led to advancements in understanding the DDR1 pathway and its implications in various biological processes.
Conclusion
Hidenobu Kamohara is a prominent inventor whose work on DDR1 has opened new avenues for research and potential therapeutic strategies. His contributions to the field are invaluable and continue to influence the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
